Abstract
Translating clinical trial results into robust treatment options remains an important issue for patients with relapsed/refractory multiple myeloma (RRMM). The availability of different treatment regimens in different countries, the heterogeneous patient population among clinical trials versus real-world data (i.e. the under-representation of frail patients or patients with severe renal impairment in several clinical trials) and the clinical practice setting contribute to discrepant results between clinical trial and real-world data. Proteasome inhibitors and immunomodulatory drugs constitute backbone agents that significantly improve outcomes among patients with RRMM. Daratumumab-based combinations have also been introduced in the real-world clinical routine. Clinical practice outside of the context of clinical trials is a constantly evolving field and real-world data should be also considered in the formulation of clinical practice guidelines and in the design of future studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
